# Toni K. Choueiri

Source: https://onco.cc/people/toni-choueiri/  
OnCo record `toni-choueiri` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads kidney cancer research worldwide, including the adjuvant pembrolizumab and belzutifan trials.

## Summary

Toni K. Choueiri is Director of the Lank Center for Genitourinary Oncology at Dana-Farber Brigham Cancer Center. He leads kidney cancer research worldwide, serving as principal investigator on CheckMate 9ER, the KEYNOTE-564 trial of adjuvant pembrolizumab and the LITESPARK studies of the HIF-2 alpha inhibitor belzutifan. His selected papers report adjuvant pembrolizumab after nephrectomy in renal cell carcinoma and belzutifan versus everolimus for advanced renal cell carcinoma. He continues to work on immunotherapy combinations, cabozantinib and HIF-2 alpha inhibition in kidney cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Lank Center for Genitourinary Oncology
- Specialisms: Kidney cancer; Immunotherapy combinations; HIF-2α

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Toni_Choueiri
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Choueiri%20TK%5BAuthor%5D

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- targets: [HIF-2α](https://onco.cc/targets/hif2a/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- trials: [CheckMate 9ER](https://onco.cc/trials/checkmate-9er/), [KEYNOTE-564](https://onco.cc/trials/keynote-564/), [LITESPARK-005](https://onco.cc/trials/litespark-005/)
- key papers: [CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer](https://onco.cc/key-papers/paper-clear-nejm-2021/), [KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery](https://onco.cc/key-papers/paper-keynote-564-nejm-2021/)

---
JSON: https://onco.cc/api/v1/entities/toni-choueiri.json